Meeting
2012 ASCO Annual Meeting
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring.
Authors
Ahmad A. Tarhini
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Ahmad A. Tarhini , Howard Edington , Lisa H. Butterfield , Hussein Tawbi , Stergios J. Moschos , Yongli Shuai , Yan Lin , Mary Horak , Saro Sarkisian , Janice Shipe-Spotloe , Christy Milburn , Cindy Sander , Jonas Talmadge Johnson , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT00972933
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8533)
DOI
10.1200/jco.2012.30.15_suppl.8533
Abstract #
8533
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
First Author: Yana Najjar
Poster
2016 ASCO Annual Meeting
Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.
First Author: Ahmad A. Tarhini
Poster
2022 ASCO Annual Meeting
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
First Author: Emilia Cocorocchio
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.
First Author: Joshua E. Reuss